Quantcast
Last updated on April 24, 2014 at 12:15 EDT

Latest Antiretroviral drug Stories

2013-12-01 08:20:25

EVRY, France, Dec. 1, 2013 /PRNewswire/ -- InnaVirVax SA today announced the initiation of a Phase 2 clinical trial assessing the therapeutic properties of the VAC-3S vaccine when combined with standard antiretroviral therapy (ART) in the course of HIV-1 infection. "On this World AIDS Day, the advancement of VAC-3S into this Phase 2 study is an important step forward. We recognize we have much work to do towards the goal of durable treatments for patients and their families...

2013-11-29 04:20:49

LONDON, November 29, 2013 /PRNewswire/ -- Maintaining antiretroviral adherence is an ongoing challenge and important aspect in achieving the World AIDS Day 2013 aim of 'Zero new HIV infections. Zero discrimination. Zero AIDS-related deaths' To mark World AIDS Day (December 1, 2013), Women for Positive Action - a global, multidisciplinary group of experts committed to addressing the specific concerns of women living with HIV - has released a commentary highlighting the...

2013-11-27 13:22:49

Long-term (24-month) supplementation with multivitamins plus selenium for human immunodeficiency virus (HIV)-infected patients in Botswana in the early stages of disease who had not received antiretroviral therapy delayed time to HIV disease progression, was safe and reduced the risk of immune decline and illness, according to a study appearing in the November 27 issue of JAMA. "Micronutrient deficiencies, known to influence immune function, are prevalent even before the development of...

2013-11-26 13:47:08

Study proposes new benchmarks for clinical treatment of HIV People with human immunodeficiency virus (HIV) run a higher risk of virologic failure than previously thought, even when their number of RNA copies of the retrovirus per millilitre of blood is slightly above the detection threshold, according to a study by Claudie Laprise at the University of Montreal's Department of Social and Preventative Medicine. Her findings were published in Clinical Infectious Diseases. The study was...

2013-11-22 08:23:50

LONDON, Nov. 22, 2013 /PRNewswire/ -- ViiV Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for Tivicay(®) (dolutegravir) for use in combination with other antiretroviral medicinal products for the treatment of HIV-infected adults and adolescents above 12 years of age. "We welcome the CHMP's positive opinion on dolutegravir - it puts us a step...

2013-11-21 11:45:08

Case Western Reserve University researchers were surprised to learn that people younger than 50 years old with HIV feel more isolated and stressed than older people with the disease. They expected their study to reveal just the opposite. “The younger, newly diagnosed individual may not know anyone in their peer group with a chronic illness, much less HIV,” said Allison Webel, PhD, RN, assistant professor at Case Western Reserve’s Frances Payne Bolton School of Nursing. Webel’s...

2013-11-14 12:21:44

Updated HIVMA Guidelines indicate doctors should focus on common health conditions The HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA) has updated its HIV care guidelines to reflect the fact that people with HIV are now living normal life spans, and their physicians need to focus on preventive care, including screening for high cholesterol, diabetes and osteoporosis. "In many HIV practices now, 80 percent of patients with HIV infection have the...

New Technology Combining Contraception, HIV And Herpes Simplex Virus-2 Prevention
2013-11-12 12:19:08

CONRAD Multipurpose prevention technologies featured at AAPS Annual Meeting and International Conference on Family Planning CONRAD Head of drug delivery, Meredith Clark, PhD, today presented preclinical data on a new intravaginal ring that provides contraception as well as HIV-1 and HSV-2 prevention at the 2013 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in San Antonio, Texas. This multipurpose prevention technology (MPT) can remain in the...

2013-11-04 08:26:00

Data Demonstrate ZFN-dependent CCR5 Modification of Long-lived Central Memory and Stem-like T-cells RICHMOND, Calif., Nov. 4, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of clinical data from its program to develop a ZFP Therapeutic(®) for HIV/AIDS. The data demonstrate a reduction in the HIV DNA reservoir since receiving SB-728-T in seven of nine HIV-infected subjects on long-term anti-retroviral therapy (ART), despite a median duration of...

2013-10-31 11:21:51

"Treatment as prevention" – early initiation of antiretroviral therapy (ART) for HIV-infected individuals with uninfected sexual partners to prevent viral transmission – appears to make economic sense, along with meeting its clinical goals of helping infected patients stay healthy and reducing transmission. A model-based analysis of data from an important clinical trial projected that early ART for such patients in both South Africa and India would be very cost-effective over the lifetime...


Latest Antiretroviral drug Reference Libraries

0_a4499f7c8759b5cbe79bad5eca319070
2011-01-26 14:08:59

Human immunodeficiency virus (HIV), a lentivirus, causes acquired immunodeficiency syndrome (AIDS) which is a condition in humans were the immune system begins to fail, leading to life-threatening opportunistic infections. Infection is transferred through bodily fluids where HIV is present as both free virus particles and within infected immune cells. The four most common routes of infection are unsafe sex, contaminated needles, breast milk, and transmission from an infected mother to her...

More Articles (1 articles) »